Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexin-G Receives FDA Fast Track Designation
Epeius’ Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The Fast Track Product designation
Epeius’ Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The Fast Track Product designation
The Valspar Corporation has reported its results for the third-quarter ended July 31, 2009. The company’s third-quarter sales totaled $794.6m, 17% lower than sales in the third quarter
Cortex has reported a net loss of $2.7m, or $0.06 per share for the quarter ended June 30, 2009, compared to a net loss of $3.9m, or $0.08
Tiens Biotech Group’s revenue for the second quarter of 2009 increased 4.6% to $20.6m, compared to $19.7m for the second quarter of 2008. For the six months ended
FDA has approved Schering-Plough’s SAPHRIS (asenapine) sublingual tablets for acute treatment of schizophrenia and manic or mixed episodes, associated with bipolar I disorder with or without psychotic features,
The FDA has advised health care practitioners and patients against using certain glucose monitoring technology, that employs a specific test strip when the patients are also receiving therapeutic
AGI Therapeutic (AGI) has reported that its co development/co-fund and licensing agreement with Axcan, for AGI-010, has been terminated by mutual consent. AGI-010 is the company’s bimodal modified
Glancy Binkow & Goldberg, a law firm has filed a class action complaint in the US District Court for the Southern District of Texas on behalf of a
The FDA has approved Saphris tablets (asenapine) to treat adults with schizophrenia and bipolar I disorder. The efficacy of Saphris in treating schizophrenia was studied in three short-term
China Shenghuo has reported an increase of 2.36% in the gross profits to $5.7m for the second quarter, as against $5.6m for the same period in 2008. For